Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate
Antibody Therapeutics · 28.03.2024 · 7 (2) · 114-122
DOI: 10.1093/abt/tbae005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 16.02.2024. Verfasst von Xiaojie Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Ins…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
In recent years, substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. However, realization of the maximum clinical use of ADCs requires surmounting extant challenges, mainly the limitations in tumor penetration capabilities when targeting solid tumors. To resolve the hurdle of suboptimal tumor penetration, miniaturized antibody fragments with engineered formats have been harnessed for ADC assembly. By virtue of their reduced molecular sizes, antibody fragment-drug conjugates hold considerable promise for efficacious delivery of cytotoxic agents, thus conferring superior therapeutic outcomes. This review will focus on current advancements in novel ADC development utilizing smaller antibody formats from ~6 to 80 kDa, with particular emphasis on single-domain antibodies, which have been widely applied in novel ADC design. Additionally, strategies to optimize clinical translation are discussed, including half-life extension, acceleration of internalization, and reduction of immunogenic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical…
- Shanghai Engineering Research Center for Synthetic Immunology, Fudan University, Shanghai 200032, China.
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Health Commission
Zitieren
APA
Ma, X., Wang, M., Ying, T., & Wu, Y. (2024). Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody Therapeutics, 7(2), 114-122. https://doi.org/10.1093/abt/tbae005
Vancouver
Ma X, Wang M, Ying T, Wu Y. Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody Therapeutics. 2024;7(2):114-122. doi:10.1093/abt/tbae005
BibTeX
@article{Ma2024,
author = {Ma, Xiaojie and Wang, Mingkai and Ying, Tianlei and Wu, Yanling},
title = {Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate},
journal = {Antibody Therapeutics},
year = {2024},
volume = {7},
number = {2},
pages = {114--122},
doi = {10.1093/abt/tbae005}
}
EUVIMED